Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 11/26/2025 has been entered.
Claim Status
Claims 1, 5-6, 8-9, 16-18, 21-24, 30, 33, 36-37, 40, 43-45 and 56-59 are pending. Claims 1, 5-6, 8-9, 16-18, 21-24, 30, 33, 36-37 and 40 have been amended. Claims 1, 5-6, 8-9, 16-18, 21-24, 30, 33, 36-37, 40, 43-45 and 56-59 are being examined in this application.
Claim Objections
Claims 5-6, 8-9, 16-18, 21-24, 30, 33, 36-37, 40, 43-45 and 56-59 are objected to because of the following informalities: Claims 5-6, 8-9, 16-18, 21-24, 30, 33, 36-37, 40 should be rewritten to recite “The compstatin analogue or pharmaceutically acceptable salt thereof according to….”. Claim 43 should be rewritten to recite “A composition comprising the compstatin analogue according to claim 1”. Claim 44 should be rewritten to recite “The composition according….”. Claim 45 should be rewritten to recite “A pharmaceutical composition comprising the compstatin analogue….”. Claims 56-59 should be rewritten to recite “The compstatin analogue or pharmaceutically acceptable salt thereof according to claim 1”. Appropriate correction is required.
Claim Rejections - 35 USC § 103
The rejection of claims 1, 9, 16 and 43-45 under 35 U.S.C. 103 as being unpatentable over Katragadda et al. and Yu et al. is withdrawn in view of the amendments to the claims.
Allowable Subject Matter
Claim 1 is allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SERGIO COFFA whose telephone number is (571)270-3022. The examiner can normally be reached M-F: 6AM-4PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, MELISSA FISHER can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SERGIO COFFA Ph.D./
Primary Examiner
Art Unit 1658
/SERGIO COFFA/Primary Examiner, Art Unit 1658
Prosecution Insights